The drug denosumab is a human, anti-RANKL monoclonal antibody that has been approved to treat osteoporosis and prevent skeletal damage in breast cancer patients (or those with other solid tumors) caused by bone metastases [108]. Here, TNFSF11 is linked to breast carcinoma.